Open AccessP1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
Author(s) -
Reiter A.,
Gotlib J.,
ÁlvarezTwose I.,
Radia D. H.,
Luebke J.,
Bobbili P. J.,
Wang A.,
Norregaard C.,
Dimitrijević S.,
Sullivan E.,
LouieGao M.,
Schwaab J.,
Galinsky I. A.,
Perkins C.,
Sperr W. R.,
Sriskandarajah P.,
Chin A.,
Sendhil S. R.,
Duh M. S.,
Valent P.,
DeAngelo D. J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846924.89785.04
Subject(s) - cladribine , medicine , midostaurin , oncology , survival analysis , systemic mastocytosis , clinical trial , randomized controlled trial , leukemia , disease